Aravive (ARAV) closed at $14.11 in the latest trading session, marking a -1.47% move from the prior day. This change was narrower than the S&P 500's daily loss of 2.59%. Meanwhile, the Dow lost 2.72%, and the Nasdaq, a tech-heavy index, lost 2.19%.
Investors will be hoping for strength from ARAV as it approaches its next earnings release. On that day, ARAV is projected to report earnings of -$0.45 per share, which would represent a year-over-year decline of 66.67%.
Any recent changes to analyst estimates for ARAV should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ARAV is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 50, putting it in the top 20% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARAVIVE, INC (ARAV) : Free Stock Analysis Report
To read this article on Zacks.com click here.